Trials / Completed
CompletedNCT06124014
CES for the Treatment of GAD in Young Adults
Cranial Electrotherapy Stimulation (CES) for the Treatment of Generalized Anxiety Disorder (GAD) in Young Adults: Double-Blind Sham-Controlled Randomized Clinical Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Electromedical Products International, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to study cranial electrotherapy stimulation (CES) to determine its effects on symptoms of anxiety in people with generalized anxiety disorder (GAD) between the ages of 18 - 21 years of age.
Detailed description
This study examines (1) the efficacy of CES with the Alpha-Stim AID ® for the treatment of GAD in young adults (18-21 years of age) in a double-blind, sham-controlled parallel group single-site clinical trial of 130 participants. Participants will be randomized into receiving either active CES (at least 200uA, up to 500uA at 0.5Hz, 60 minutes daily for six weeks) or sham CES with the Alpha-Stim AID ® device at-home. Clinical assessments of anxiety symptoms are performed at Screening (for eligibility), Baseline, Follow-Up 1 (at completion of intervention, 6 weeks after initial stimulation), and Follow-Up 2 (12 weeks after initial stimulation). Additional assessments of depression symptoms and quality of life are included. Resting-state EEG will be collected at baseline and Follow-Up 1 (in up to 60 participants) for exploratory investigation of mechanism of action.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | At-Home Stimulation | The stimulation paradigm in this trial consists of six weeks of daily, 60-minute at-home stimulation sessions. |
Timeline
- Start date
- 2024-01-26
- Primary completion
- 2025-12-17
- Completion
- 2026-01-21
- First posted
- 2023-11-09
- Last updated
- 2026-03-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06124014. Inclusion in this directory is not an endorsement.